SCHEMBL15050751

SCHEMBL15050751

CC(O)c1cn(-c2ccnc(Cl)c2)nc1-c1ccccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.34
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
MAPK14 Q16539 1/20 0.33
MAPT P10636 2/20 0.33
ALPL P05186 1/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
PTPN1 P18031 1/20 0.32
ALDH1A1 P00352 4/20 0.32
DGAT2 Q96PD7 4/20 0.31
KDM5B Q9UGL1 1/20 0.31
GLA P06280 1/20 0.31
DPP4 P27487 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051508 0.79 SCN9A (0.37) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL15051894 0.78 ALDH1A1 (0.47) KDM4EMEN1KMT2ALMNAMAPT
SCHEMBL15051624 0.77 KDM4E (0.45) KDM4EALDH1A1DPP4
SCHEMBL15051300 0.76 MAPT (0.51) KDM4EMEN1KMT2ALMNAMAPT
SCHEMBL15051665 0.76 PTGS2 (0.46) KDM4EMEN1KMT2ALMNARAB9A
SCHEMBL15051559 0.74 AKT1 (0.36) KDM4EMEN1KMT2ALMNARAB9A
SCHEMBL15051049 0.74 KDM4E (0.36) KDM4EMEN1KMT2ALMNARAB9A
SCHEMBL15051533 0.73 ALDH1A1 (0.39) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL15050926 0.71 EGLN1 (0.39) MEN1KMT2AALPLKDM5B
SCHEMBL15050714 0.71 IKBKB (0.39) KDM4EGAADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793880-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 KCNA5 3596/4885KDM4E 1614/4885MEN1 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.